DOI 10.1016/j.jaad.2025.11.026
A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer.
Аннотация
BACKGROUND
Minimally invasive treatments are increasingly needed for low to intermediate risk cutaneous squamous cell carcinoma (cSCC), particularly in patients with high disease burden.
OBJECTIVE
To evaluate the efficacy and tolerability of intralesional talimogene laherparepvec (TVEC) as a novel immunotherapeutic approach for cSCC in patients seeking non-surgical options.
METHODS
Up to 5 histologically confirmed invasive low to intermediate risk cSCC tumors per patient were treated and referred to as target lesions injected (TLIs). Intralesional TVEC was administered every 2 weeks, up to 4 injections per lesion. Response rate was assessed by subject and individual TLIs.
RESULTS
Eleven patients with 24 cSCC tumors were enrolled. ORR was 100% by patient (11/11) and by tumor (24/24) (95% CI = 76.2%). A confirmed complete response occurred in 90.9% of patients (10/11; 95% CI = 58.7%, 99.8%) involving 23 of 24 tumors. Median duration of response was 212 days (range = 140-236 days). Two years post-treatment, patients showed no recurrence and significantly fewer new primary invasive cSCCs.
LIMITATIONS: Nonrandomized, small sample size, and lesion site exclusions.
CONCLUSION
Intralesional TVEC demonstrated promising efficacy and tolerability as a minimally invasive treatment for low to intermediate risk cSCC with potential to reduce subsequent incidence rates.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.